BIO logo

BIO-RAD LABORATORIES-A

BIONYSE
๐Ÿ† #872 by market capEarnings Oct 22 ยท PostUS Equity
$379.79โ–ฒ $2.13 (+0.56%)
Live
๐Ÿ””
Track BIO
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 0.6%
7dโ–ฒ 0.0%
14dโ–ฒ 0.5%
30dโ–ผ 2.1%
ytdโ–ฒ 25.1%
1yโ–ฒ 41.1%
๐ŸฆMarket Cap
$10.22B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
+0.7%
Slowing
๐Ÿ“ŠGross Margin
51.9%
Healthy
๐Ÿ’ตFCF Margin
13.6%
Healthy
โš–๏ธP/S Ratio
3.9x
Fair
Otter Score
68
Fair

Trading Snapshot

Day Range
$377.69 โ€“ $385.85
52-Week Range
$236.73 โ€“ $396.23
Volume
$2.43B
Avg Volume
$2.64B
Shares Outstanding
26.9M
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$2.58B
Last Q Revenue
$651M
P/E Ratio
45.3
P/S Ratio
3.9x
EPS (TTM)
$8.32
Dividend Yield
0.00%
Dilution (1yr)
โˆ’3.5%

Why Investors Own BIO

  • โœ“High-growth profile โ€” revenue up +27.5% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 40% gross margin and 22% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BIO logo

BIO-RAD LABORATORIES-A

BIO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.6Bโ–ฒ +0.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
52.0%โ–ผ โˆ’3.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
$271Mโ–ฒ +0.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$375Mโ–ฒ +40.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
27.0Mโ–ผ โˆ’3.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
โˆ’$999Mโ–ผ โˆ’$113M YoY
StockOtter ยท stockotter.space

About BIO-RAD LABORATORIES-A

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
68/100

Analyst Ratings

โ“˜
Consensus
Buy
10 analysts
Strong Buy1
Buy4
Hold4
Sell1
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

GlobeNewsWireยท16h ago

BIO-key Partners with Al Majlis Group to Expand Identity Security Across Arabian Gulf

BIO-key (BKYI) Partners with Al Majlis Group, Founded by His Excellency Dherar Belhoul Al Falasi, to Expand Identity Security Across Arabian Gulf Region.

MarketBeatยท3d ago

Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth

Bio-Rad Laboratories NYSE: BIO is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective appro

Seeking Alphaยท5d ago

Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

Zacks Investment Researchยท6d ago

Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now

BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.

GlobeNewsWireยท6d ago

BIO-key Receives FIDO Alliance Full Certification for Passkey:YOUโ„ข Authentication, Unlocking New Markets Including Agentic AI Authenticated Controls

HOLMDEL, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BIO-keyยฎ International, Inc. (NASDAQ: BKYI), a global provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless a

Business Wireยท13d ago

Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. L